Evidence map›Paper›PMID 21762125›Full record

ArticleClinical and experimental immunology2011

Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome.

R Bertelli, M Bodria, M Nobile, S Alloisio, R Barbieri, G Montobbio, P Patrone, G M Ghiggeri

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02455908 (Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02455908 phase1 / phase2completednot on this mapstarted 2012, after this paper: background citation

Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome

TypeinterventionalSponsorIstituto Giannina GasliniRan2012 to 2012Enrolled5ConditionsNephrotic SyndromeArmsProleukin®
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Rituximab in children with resistant idiopathic nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2012
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

R BertelliDivision of Nephrology, Dialysis, Transplantation and Laboratory on Pathophysiology of Uremia Division of Anesthesiology, Istituto Giannina Gaslini IRCCS, Genova, Italy.
M Bodria
M Nobile
S Alloisio
R Barbieri
G Montobbio
P Patrone
G M Ghiggeri
Czech Academy of Sciences, Institute of Biophysics · CZIstituti di Ricovero e Cura a Carattere Scientifico · ITNational Academies of Sciences, Engineering, and Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of the oxidative burst and failure of CD4(+) CD25(+) cell regulation have been implicated in idiopathic nephrotic syndrome (iNS). The intimate mechanism is, however, unknown and requires specifically focused studies. We investigated reactive oxygen species (ROS) generation [di-chlorofluorescein-diacetate (DCFDA)] fluorescence assay and the regulatory adenosine 5'-triphosphate (ATP) pathways in the blood of 41 children with iNS, utilizing several agonists and antagonists of nucleotide/nucleoside receptors, including the addition of soluble apyrase. The CD4(+) CD25(+) CD39(+) /CD73(+) expression was determined in vivo in parallel during disease activity. Overall, we found that the percentage of CD39(+) CD4(+) CD25(+) was reduced markedly in iNS by 80% (3·43±0·04% versus 13·14±0·07% of total lymphocytes, P<0·001). In these patients, reactive oxygen species (ROS) generation by polymorphonuclear neutrophils (PMN) at rest was a function of apyrase (CD39) expressed by CD4(+) CD25(+) , with higher rates in patients with very low CD39(+) CD4(+) CD25(+) levels (<7·5%). Addition of apyrase reduced ROS generation by 40% in both iNS and controls and was mainly effective in patients. The quota of ROS surviving ATP elimination was higher still in iNS. In vitro studies to limit ROS generation with adenosine analogues (2'-chloroadenosine and 5'-N-ethylcarboxamidoadenosine) produced minor effects. At variance, antagonizing ATP efflux with carbenoxolone or by antagonizing ATP effects (Brilliant Blue G, KN62 and A437089) reduced ROS generation comparable to apyrase. These results confirm a key role of ATP in the regulation of innate immunity and minimize the effect of adenosine. Decreased CD39(+) CD4(+) CD25(+) expression in iNS highlights an impairment of ATP degradation in this pathology. However, high ROS surviving ATP consumption implies a major role of other regulatory pathways.

Indexed as

Immunity, InnateAdenosine-5'-(N-ethylcarboxamide)Adenosine TriphosphateAntigens, CDApyraseCD4 Lymphocyte CountCells, CulturedChildChild, PreschoolFemaleFlow CytometryFluoresceinsHumansMaleNephrosis, LipoidNephrotic SyndromeAdenosine-5'-(N-ethylcarboxamide)Adenosine TriphosphateAntigens, CDApyrasediacetyldichlorofluoresceinFluoresceinsPurinergic P1 Receptor AgonistsPurinergic P1 Receptor AntagonistsReactive Oxygen SpeciesReceptors, Purinergic P1Receptors, Purinergic P2

Identifiers

PMID21762125
PMCPMC3193919
OpenAlexW1480409613

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.